Synapse - Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)

Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) Meeting Abstract

Authors:	Omuro, A. M. P.; Beal, K.; Karimi, S.; Correa, D.; Chan, T. A.; DeAngelis, L. M.; Gavrilovic, I. T.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T. J.; Mellinghoff, I. K.; Grommes, C.; Panageas, K.; Reiner, A. S.; Barradas, R.; Abrey, L. E.; Gutin, P. H.
Abstract Title:	Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
Meeting Title:	47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	29
Issue:	15 Suppl.
Meeting Dates:	2011 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2011-05-20
Language:	English
ACCESSION:	WOS:000208880301244
PROVIDER:	wos
DOI:	10.1200/jco.2011.29.15_suppl.2028
Notes:	Meeting Abstract: 2028 -- Source: Wos